Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies.

ABSTRACT:

Introduction

Vancomycin-resistant enterococci (VRE) are a leading cause of nosocomial infections because of the limited number of effective therapeutic options. In an effort to repurpose FDA-approved drugs against antibiotic-resistant bacteria, auranofin has been identified as a potent drug against VRE.

Methods and results

The present study determined that auranofin's antibacterial activity was not affected when evaluated against a higher inoculum size of VRE (~10⁷ CFU/mL), and auranofin successfully reduced the burden of stationary phase VRE cells via a time-kill assay. In addition, auranofin reduced VRE production of key virulence factors, including proteases, lipase and haemagglutinin. The promising features of auranofin prompted evaluation of its in vivo effic

SUBMITTER: Abutaleb NS 

PROVIDER: S-EPMC7073294 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature